scispace - formally typeset
M

Michael Goitein

Researcher at Harvard University

Publications -  162
Citations -  12614

Michael Goitein is an academic researcher from Harvard University. The author has contributed to research in topics: Radiation therapy & Proton therapy. The author has an hindex of 60, co-authored 162 publications receiving 12206 citations. Previous affiliations of Michael Goitein include University of Zurich.

Papers
More filters
Journal ArticleDOI

Relative biological effectiveness (RBE) values for proton beam therapy.

TL;DR: There is too much uncertainty in the RBE value for any human tissue to propose RBE values specific for tissue, dose/fraction, proton energy, etc, and experimental in vivo and clinical data indicate that continued employment of a generic RBEvalue is reasonable.
Journal ArticleDOI

Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations.

TL;DR: A method of calculating complication probabilities for inhomogeneously irradiated normal tissues is presented, using examples from an NCI 3-D treatment planning contract.
Journal ArticleDOI

Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation.

TL;DR: The main effect of organ motion in IMRT is an averaging of the dose distribution without motion over the path of the motion, the same as for treatments with conventional beams.
Journal ArticleDOI

A pencil beam algorithm for proton dose calculations

TL;DR: A pencil beam algorithm for proton dose calculations which takes accurate account of the effects of materials upstream of the patient and of the air gap between them and the patient is developed.
Journal ArticleDOI

Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

TL;DR: An increase in prostate tumor dose by external beam of 12.5% to 75.6 Cobalt Gray Equivalent using a conformal perineal proton boost significantly improved local control only in patients with poorly differentiated tumors.